Optimal Use of Fluoroquinolones in the Intensive Care Unit Setting

Critical Care Clinics

Volumn 27, Issue 1, 2011, Pages 95-106

  Rotschafer, John C ^a   Ullman, Mary A ^b   Sullivan, Christopher J ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b REGIONS HOSPITAL   (United States)

^c Fairview Hospital   (United States)

Author keywords

Fluoroquinolone antibiotics; Intensive care unit; Pharmacodynamics

Indexed keywords

AMINOGLYCOSIDE; ANTACID AGENT; ANTIINFECTIVE AGENT; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; IRON; LEVOFLOXACIN; METAL ION; MOXIFLOXACIN; MULTIVITAMIN; NORFLOXACIN; OFLOXACIN; POLYMYXIN; PROTEIN PARC; PROTEIN PARE; SUCRALFATE; TROVAFLOXACIN;

ACINETOBACTER INFECTION; ANAEROBIC INFECTION; ANIMAL HUSBANDRY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ATYPICAL MYCOBACTERIOSIS; ATYPICAL MYCOBACTERIUM; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; CONFUSION; CONVULSION; CRYSTALLURIA; DIZZINESS; DNA SUPERCOILING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG SENSITIVITY; FOOD AND DRUG ADMINISTRATION; GLUCOSE HOMEOSTASIS; HEADACHE; HEMOLYTIC UREMIC SYNDROME; HOSPITAL; HUMAN; HYPERSENSITIVITY REACTION; INSOMNIA; INTENSIVE CARE UNIT; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; LENGTH OF STAY; LIVER TOXICITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; MULTIDRUG RESISTANCE; NAUSEA; NIGHTMARE; NONHUMAN; NURSING HOME; OPTIMAL DRUG DOSE; PARANOIA; PERIPHERAL NEUROPATHY; PHOTOTOXICITY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QT PROLONGATION; REVIEW; SEIZURE; SIDE EFFECT; STENOTROPHOMONAS MALTOPHILIA; TASTE DISORDER; TENDINITIS; TENDON INJURY; TUBE FEEDING; TUBERCULOSIS; URINARY TRACT INFECTION; VOMITING;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INTENSIVE CARE UNITS;

EID: 78649928690     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2010.11.005     Document Type: Review

References (37)

1. Pepin J., Saheb N., Andree-Coulombe M., et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005, 41(11):2365-2371.
2. Graffunder E.M., Venezia R.A. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother 2002, 49(6):999-1005.
3. Mihu C.N., Rhomberg P.R., Jones R.N., et al. Escherichia coli resistance to quinolones at a comprehensive cancer center. Diagn Microbiol Infect Dis 2010, 67:266-269.
4. Gore J., Bryant Z., Stone M.D., et al. Mechanochemical analysis of DNA gyrase using rotor bead tracking. Nature 2006, 439:100-104.
5. Champoux J.J. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 2001, 70:369-413.
6. Wang J.C. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 2002, 3(6):430-440.
7. Sicor-Pharmaceuticals. Ciprofloxacin medication Information. Irvine (CA); 2006.
8. Schering-Plough. Avelox medication information sheet. Kenilworth: Bayer Healthcare; 2008.
9. Ortho-McNeil-Janssen Pharmaceuticals I. Levaquin highlights of prescribing information. Raritan; 2009.
10. Ortho-McNeil. Levaquin 360 information. 2010.
11. Wener K.M., Schechner V., Gold H.S., et al. Treatment with fluoroquinolones or with β-lactam-β-lactamase inhibitor combinations is a risk factor for isolation of extended-spectrum-β-lactamase-producing Klebsiella species in hospitalized patients. Antimicrob Agents Chemother 2010, 54(5):2010-2016.
12. Potron A., Poirel L., Bernabeu S., et al. Nosocomial spread of ESBL-positive Enterobacter cloacae co-expressing plasmid-mediated quinolone resistance Qnr determinants in one hospital in France. J Antimicrob Chemother 2009, 64(3):653-654.
13. Wright D.H., Bown G.H., Peterson M.L., et al. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 2000, 46:669-683.
14. Oelschlaeger P., Ai N., DaPrez K.T., et al. Evolving carbapenemases: can medicinal chemists advance one step ahead of the coming storm?. J Med Chem 2010, 53:3013-3027.
15. Peterson M.L., Houde L.B., Wright D.H., et al. Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposure. Antimicrob Agents Chemother 1999, 43(9):2251-2255.
16. Peterson M.L., Houde L.B., Wright D.H., et al. Pharmacodynamics of trovafloxacin and levofloxacin against B. fragilis in an in-vitro pharmacodynamic model. Antimicrob Agents Chemother 2001, 46:203-210.
17. Chan E.D., Laurel V., Strand M.J., et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004, 169:1103-1109.
18. Ziha-Zarifi I., Lanes C., Kohler T., et al. In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM. Antimicrob Agents Chemother 1999, 43(2):287-291.
19. Le Thomas I., Couetdic G., Clermont O., et al. In vivo selection of a target/efflux double mutant of Pseudomonas aeruginosa by ciprofloxacin therapy. J Antimicrob Chemother 2001, 48(4):553-555.
20. Drlica K., Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 1997, 61(3):377-392.
21. Schmitz F.J., Hofmann B., Hansen B., et al. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 1998, 41:481-484.
22. Martinez-Martinez L., Pascual A., Jacoby G.A. Quinolone resistance from a transferable plasmid. Lancet 1998, 351(9105):797-799.
23. Rotschafer J.C., Zabinski R.A., Walker K.J., et al. Pharmacotherapy and pharmacodynamics in the management of bacterial infection. J Clin Pharmacol 1992, 37:436-440.
24. Yang J.C., Tsuji B.T., Forrest A. Optimizing use of quinolones in the critically ill. Semin Respir Crit Care Med 2007, 28:586-595.
25. Forrest A., Nix D.E., Ballow C.H., et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993, 37(5):1073-1081.
26. Preston S.L., Drusano G.L., Berman A.L., et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998, 279(2):125-129.
27. Drusano G.L., Preston S., Fowler C., et al. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 2004, 189:1590-1597.
28. Ambrose P.G., Grasela D.M., Grasela T.H., et al. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001, 45(10):2793-2797.
29. Gumbo T., Louie A., Deziel M., et al. Selection of a moxifloxacin dose that suppresses drug resistance in M. tuberculosis by use of an in-vitro pharmacodynamic model and mathematical modeling. J Infect Dis 2004, 190:1642-1651.
30. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-acquired Pneumonia Study Group. Intensive Care Med 1996, 22(5):387-394.
31. Dupont H., Mentec H., Sollet J.P., et al. Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med 2001, 27(2):355-362.
32. Kollef M., Sherman G., Ward S., et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999, 115(2):462-474.
33. Luna C., Vujacich P., Niederman M.S., et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997, 111(3):676-685.
34. Rello J., Gallego M., Mariscal D., et al. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997, 156(1):196-200.
35. Ruiz M., Torres A., Ewig S., et al. Noninvasive versus invasive microbial investigation in ventilator-associated pneumonia: evaluation of outcome. Am J Respir Crit Care Med 2000, 162(1):119-125.
36. Kollef M., Morrow L.E., Niederman M.S., et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest 2006, 129(5):1210-1218.
37. Madaras-Kelly K.J., Ostergaard B.E., Hovde L.B., et al. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob Agents Chemother 1996, 40(3):627-632.